Albemarle Corporation
Second Quarter 2018 Earnings
and Non-GAAP Reconciliations

Conference Call/Webcast

Wednesday, August 8th, 2018

9:00am ET



Forward-Looking Statements

Some of the information presented in this presentation, the conference call and discussions that follow, including, without limitation, statements with respect to product development, market trends, price, expected growth and earnings, demand for our products, capital projects, tax rates, stock repurchases, dividends, cash flow generation, economic trends, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed.

Factors that could cause actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products or the end-user markets in which our products are sold; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; increases in the cost of raw materials and energy, and our ability to pass through such increases to our customers; changes in our markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of regulatory proceedings, claims or litigation; the occurrence of cyber-security breaches, terrorist attacks, industrial accidents, natural disasters or climate change; hazards associated with chemicals manufacturing; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings and changes in tax laws and rates; changes in monetary policies, inflation or interest rates that may impact our ability to raise capital or increase our cost of funds, impact the performance of our pension fund investments and increase our pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions we may make in the future; the ability to successfully execute, operate and integrate acquisitions and divestitures; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this presentation. We assume no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.



Non-GAAP Financial Measures

It should be noted that Adjusted net income attributable to Albemarle Corporation ("Adjusted earnings"), Adjusted diluted earnings per share attributable to Albemarle Corporation, Adjusted effective income tax rates, segment operating profit, segment income, pro-forma net sales, net sales excluding the impact of foreign exchange translation ("ex FX"), EBITDA, Adj. EBITDA by operating segment, EBITDA margin, Adj. EBITDA margin, pro-forma Adj. EBITDA, pro-forma Adj. EBITDA margin, Adj. EBITDA excluding the impact of foreign exchange translation ("ex FX"), adj. EBITDA margin excluding the impact of foreign exchange translation ("ex FX"), net debt to Adj. EBITDA, gross debt to Adj. EBITDA, free cash flow, and Adjusted free cash flow are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These measures are presented here to provide additional useful measurements to review our operations, provide transparency to investors and enable period-to-period comparability of financial performance. The Company's chief operating decision maker uses these measures to assess the ongoing performance of the Company and its segments, as well as for business and enterprise planning purposes.


A description of these and other non-GAAP financial measures that we use to evaluate our operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, can be found in the Appendix to this presentation, which is posted in the Investors section of our website at www.albemarle.com, under "Non-GAAP Reconciliations" under "Financials." The Company does not provide a reconciliation of forward looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the Company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the Company's results calculated in accordance with GAAP.



Key Messages




Second Quarter 2018 Financial Highlights



Results driven by double digit Adjusted EBITDA¹ growth in Lithium, Bromine and Catalysts

Segment Quarterly Highlights



Core Business Performance -Second Quarter 2018 Lithium – \$142M Adj. EBITDA³, up 23% YoY; 45% Adj. EBITDA³ margin


Bromine Specialties – \$69M Adj. EBITDA³,up 12%; 31% Adj. EBITDA³ margin

Catalysts – \$75M Adj. EBITDA³, up 30%²; 26% Adj. EBITDA³ margin



Second Quarter 2018 Adjusted EBITDA¹ Bridge

Q2 2018: Adjusted EBITDA¹ growth² of \$50 million, 24% yoy





¹Non-GAAP measure. See Non-GAAP reconciliations in Appendix. Bridge numbers may not reconcile due to rounding. ²Year-over-year growth calculated against pro-forma Q2 2017 which excludes net impact from divested business (Polyolefin Catalysts & Components). Pro-forma reconciliations in Appendix.

Lithium

Q2	2018 Perfo	rmance	
(\$ in millions)	Q2 2018	Q2 2017	Δ
Net Sales	\$318	\$244	30%
Net Sales ex FX ¹	\$310		27%
Adj. EBITDA ²	\$142	\$115	23%
Adj. EBITDA ex FX ¹	\$141		22%
Adj. EBITDA Margin ²	45%	47%	(265 bps)
Adj. EBITDA Margin ex FX ¹	45%		(179 bps)



Performance Drivers

- Q2 2018 Lithium net sales growth driven by volume (15%) and pricing (12%)
- Strong demand continues across the portfolio with assets and tolling partners running at max rates
- Capital projects proceeding as planned, Xinyu II front end commissioned in Q2 2018 and expect mechanical completion and commissioning of back end during Q4 2018



Bromine Specialties

Q2	2018 Perfo	rmance	
(\$ in millions)	Q2 2018	Q2 2017	Δ
Net Sales	\$221	\$204	8%
Net Sales ex FX ¹	\$217		7%
Adj. EBITDA ²	\$69	\$62	12%
Adj. EBITDA ex FX ¹	\$67		7%
Adj. EBITDA Margin ²	31%	30%	102 bps
Adj. EBITDA Margin ex FX ¹	31%		23 bps




Performance Drivers

- Q2 2018 Bromine Specialties net sales growth driven by volume (3%) and pricing (3%)
- Higher pricing is offsetting higher input costs driven by crude oil chain
- Solid demand for flame retardants continues while China production remains low



Catalysts

Q2 2018 Performance											
(\$ in millions)	Q2 2018	Q2 2017	Pro-forma ³ Q2 2017	Δ vs Pro-forma 3 Q2 2017							
Net Sales	\$285	\$258	\$233	23%							
Net Sales ex FX ¹	\$280			20%							
Adj. EBITDA ²	\$75	\$67	\$58	30%							
Adj. EBITDA ex FX ¹	\$75			30%							
Adj. EBITDA Margin ²	26%	26%	25%	156 bps							
Adj. EBITDA Margin ex FX¹	27%			191 bps							



Performance Drivers

- Q2 2018 Catalysts net sales growth driven by volume (16%) and pricing/mix (2%)
- Adjusted EBITDA² growth from higher net sales, Hurricane Harvey insurance claim payment (\$2 million), partially
 offset by Force Majeure in Curatives due to a raw material shortage (\$5 million)



Cash Flow and Net Debt

Six Months Ended June	e 30	
(\$ in millions)	<u>2018</u>	<u>2017</u>
Net Cash from Operations	\$224	(\$54)
Less: Capital Expenditures	(281)	(98)
Add Back: Pension Contributions ¹	7	11
Free Cash Flow ²	(\$50)	(\$141)
Non-recurring and other unusual cash items	40	59
Cash taxes on repatriation/Chemetall® sale	40	255
Adjusted Free Cash Flow ²	\$30	\$173

Selected Financial Metrics	
(\$ in millions)	(as of 06/30/2018)
Dividends Paid:	\$72
Dividend Growth (Y/Y) ³ :	5%
Cash Balance:	\$908
Gross Debt ⁴ :	\$1,615
Net Debt to Adj. EBITDA ⁵ :	0.8x





Initiating \$250 million accelerated share repurchase program, subject to market conditions, to be completed by year end Expect Net Debt to Adj. EBITDA⁵ to end year at ~1.2x



¹2017 amount includes \$5 million related to company employees in the German multiemployer plan and \$6 million related to U.S. defined benefit and other postretirement plans.

²Non-GAAP measure. See Non-GAAP reconciliations in Appendix.

⁴Excludes JV debt not guaranteed by Company.

⁵Gross Debt to Adj. EBITDA and Net Debt to Adj. EBITDA ratios are based on the bank covenant definition. See appendix for reconciliations.

Full Year 2018 Business Guidance vs 2017

Business Unit	Prior Outlook	Updated Outlook	Business Environment
Lithium	•	•	 FY 2018 Adj. EBITDA¹ expected to increase low-to-mid 20's on % basis vs prior year Expect 1H 2018 to be similar to 2H 2018; Q3 similar to Q1 and Q4 similar to Q2 Favorable outlook driven by strong volume and price improvements, primarily in battery grade product portfolio
Bromine Specialties			 FY 2018 Adj. EBITDA¹ expected to be up high single-digit vs prior year Improved outlook driven by solid demand for flame retardants and higher pricing in some derivatives, partially offset by higher raw material and freight costs
Catalysts ²	•	1	 FY 2018 Adj. EBITDA¹ expected to increase high single-digit vs prior year on proforma² basis driven by higher volume, favorable product mix and higher pricing in FCC Q4 2018 expected to be stronger than Q3 2018 Now expect ~\$5 million (vs \$10 million previously) unfavorable impact to Adj. EBITDA¹ in FY2018 due to raw material shortage in Curatives product line Anticipate favorable benefit of \$5 million from Hurricane Harvey insurance settlements with \$2 million already received in Q2 2018





Better than 2017 and Prior Outlook



Full Year 2018 Guidance

	FY 2017	FY 2017 Pro Forma ³	Prior FY 2018 Guidance⁴		Updated FY 2018 Guidance⁴	Updated 2018 Guidance vs FY 2017 Pro-Forma ³
Net Sales	\$3.07B	\$3.00B	\$3.2 - \$3.4B	A	\$3.3 - \$3.5B	10% – 17%
Adjusted EBITDA ¹	\$885M	\$859M	\$955 - \$1,005M		\$990 - \$1,020M	15% – 19%
Adjusted EBITDA Margin ¹	29%	29%	29% – 30%	=	29% – 30%	
Adjusted Diluted EPS ¹	\$4.59	\$4.40	\$5.10 - \$5.40	A	\$5.30 - \$5.50	20% – 25%
D&A	\$197	\$192	N/A		\$195 - \$205	
Net Cash from Operations ²	\$304M	\$278M	\$660 - \$730M	=	\$660 - \$730M	
Capital Expenditures	\$318M	\$313M	\$800 - \$900M	=	\$800 - \$900M	
Adjusted Free Cash Flow ²	\$354M	\$333M	(\$150) - \$50M	=	(\$150) - \$50M	

¹Non-GAAP measure. See Non-GAAP reconciliation in Appendix for 2017 figures.



²Free Cash Flow is a non-GAAP measure defined as Net Cash from Operations, add back pension and post-retirement contributions and subtract capital expenditures. See slide 11 for details.

³The FY 2017 Pro Forma calculation excludes the financial contribution from Polyolefin Catalyst & Components for the final nine months of 2017 because Albemarle closed the sale by the end of 1Q 2018. Pro Forma FY 2017 Net Cash from Operations is calculated by subtracting the Adjusted EBITDA associated with the Polyolefin Catalysts & Components. Pro Forma FY 2017 Adjusted Free Cash Flow calculated by subtracting the Adjusted EBITDA and adding back the Capital Expenditures associated with the Polyolefin Catalysts & Components.

⁴FY 2018 Guidance includes financial contribution from Polyolefin Catalysts & Components during Q1 2018 only.



www.albemarle.com

Appendix

Non-GAAP Reconciliations and Supplemental Information



Adjusted Net Income - Pro-forma

Pro-forma adjusted diluted earnings per share

Weighted-average common shares outstanding - diluted

	 Jun	e 30,	
(\$ in thousands)	2018		2017
Net income attributable to Albemarle Corporation	\$ 302,461	\$	103,333
Add back:			
Non-operating pension and OPEB items (net of tax)	(1,873)		(589)
Non-recurring and other unusual items (net of tax)	 (150,618)		23,738
Adjusted net income attributable to Albemarle Corporation	149,970		126,482
Pro-forma: Net impact of income from divested business (net of tax)	 		(7,903)
Pro-forma adjusted net income attributable to Albemarle Corporation	\$ 149,970	\$	118,579
Adjusted diluted earnings per share	\$ 1.36	\$	1.13

Three Months Ended

1.36 \$

110.659

1.06

112.105

See above for a reconciliation of adjusted net income and pro-forma adjusted net income, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP. Adjusted earnings is defined as earnings before the non-recurring, other unusual and non-operating pension and OPEB items as listed above. Pro-forma adjusted net income is defined as earnings before the non-recurring, other unusual and non-operating pension and OPEB items, and the net impact of the divested business.



EBITDA and Adjusted EBITDA - Pro-forma

	Three Mo	nths E	Ended
	Ju	ne 30,	
(\$ in thousands)	 2018		2017
Net income attributable to Albemarle Corporation	\$ 302,461	\$	103,333
Add back:			
Interest and financing expenses	13,308		14,590
Income tax expense	80,102		23,130
Depreciation and amortization	50,474		49,122
EBITDA	446,345		190,175
Non-operating pension and OPEB items	(2,204)		(1,053)
Non-recurring and other unusual items (excluding items associated with interest expense)	(185,579)		29,819
Adjusted EBITDA	258,562		218,941
Pro-forma: Net impact of adjusted EBITDA from divested business	_		(9,766)
Pro-forma adjusted EBITDA	\$ 258,562	\$	209,175
Net sales	\$ 853,874	\$	737,258
Pro-forma: Net impact of net sales from divested business	_		(25,731)
Pro-forma net sales	\$ 853,874	\$	711,527
EBITDA margin	52.3%		25.8%
Adjusted EBITDA margin	30.3%		29.7%
Pro-forma adjusted EBITDA margin	30.3%		29.4%

See above for a reconciliation of EBITDA, adjusted EBITDA, and pro-forma adjusted EBITDA, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP. EBITDA is defined as Net income attributable to Albemarle Corporation before interest and financing expenses, income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA before the non-recurring, other unusual and non-operating pension and OPEB items as listed below. Pro-forma adjusted EBITDA is defined as adjusted EBITDA before the net impact of EBITDA from the divested business.

See above for a reconciliation of pro-forma net sales, the non-GAAP financial measure, to net sales, the most directly comparable financial measure calculated and reported in accordance with GAAP. Proforma net sales is defined as net sales before the net impact of net sales from the divested business.



Adjusted EBITDA - by Segment (three months ended June 30)

(\$ in thousands)	Lithium	Bro	omine Specialties		Catalysts	;	Reportable Segments Total	All Other	Corporate	Co	nsolidated Total
Three months ended June 30, 2018:											
Net income (loss) attributable to Albemarle Corporation	\$ 117,292	\$	59,673	\$	280,887	\$	457,852	\$ (2,079)	\$ (153,312)	\$	302,461
Depreciation and amortization	24,325		9,694		12,920		46,939	1,978	1,557		50,474
Non-recurring and other unusual items	_		_		(218,705)		(218,705)	_	33,126		(185,579)
Interest and financing expenses	_		_		_		_	_	13,308		13,308
Income tax expense	_		_		_		_	_	80,102		80,102
Non-operating pension and OPEB items	_		_		_		_	_	(2,204)		(2,204)
Adjusted EBITDA	\$ 141,617	\$	69,367	\$	75,102	\$	286,086	\$ (101)	\$ (27,423)	\$	258,562
Three months ended June 30, 2017:											
Net income (loss) attributable to Albemarle Corporation	\$ 81,819	\$	51,739	\$	53,994	\$	187,552	\$ 152	\$ (84,371)	\$	103,333
Depreciation and amortization	21,460		10,336		13,433		45,229	2,292	1,601		49,122
Non-recurring and other unusual items	11,921		_		_		11,921	_	17,898		29,819
Interest and financing expenses	_		_		_		_	_	14,590		14,590
Income tax expense	_		_		_		_	_	23,130		23,130
Non-operating pension and OPEB items	_		_		_		_	_	(1,053)		(1,053)
Adjusted EBITDA	\$ 115,200	\$	62,075	\$	67,427	\$	244,702	\$ 2,444	\$ (28,205)	\$	218,941
Pro-forma: Net impact of adjusted EBITDA from divested business	_		_	_	(9,766)		(9,766)	_	_		(9,766)
Pro-forma adjusted EBITDA	\$ 115,200	\$	62,075	\$	57,661	\$	234,936	\$ 2,444	\$ (28,205)	\$	209,175

See above for a reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reporting in accordance with GAAP. EBITDA is defined as earnings before interest and financing expenses, income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA before the non-recurring, other unusual and non-operating pension and OPEB items as listed above.

Adjusted EBITDA - Margin by Segment (three months ended June 30)

(\$ in thousands)	Lithium	Bromine Specialties	Catalysts	s	Reportable Segments Total	All Other	Co	nsolidated Total
Three months ended June 30, 2018:								
Net sales	\$ 317,563	\$ 220,514	\$ 284,966	\$	823,043	\$ 30,748	\$	853,874
Net income (loss) attributable to Albemarle Corporation	36.9%	27.1%	98.6%		55.6%	(6.8)%		35.4%
Depreciation and amortization	7.7%	4.4%	4.5%		5.7%	6.4%		5.9%
Non-recurring and other unusual items	—%	—%	(76.7)%		(26.6)%	—%		(21.7)%
Interest and financing expenses	-%	-%	—%		—%	—%		1.6%
Income tax expense	—%	-%	—%		-%	—%		9.4%
Non-operating pension and OPEB items	—%	-%	-%		-%	—%		(0.3)%
Adjusted EBITDA Margin	44.6%	31.5%	26.4%		34.8%	(0.3)%		30.3%
		 _	 _		_	_		
Three months ended June 30, 2017:								
Net sales	\$ 243,821	\$ 203,945	\$ 258,255	\$	706,021	\$ 30,704	\$	737,258
Pro-forma: Net impact of net sales from divested business	 		(25,731)		(25,731)	 		(25,731)
Pro-forma net sales	\$ 243,821	\$ 203,945	\$ 232,524	\$	680,290	\$ 30,704	\$	711,527
Net income (loss) attributable to Albemarle Corporation	33.6%	25.4%	20.9%		26.6%	0.5%		14.0%
Depreciation and amortization	8.8%	5.1%	5.2%		6.4%	7.5%		6.7%
Non-recurring and other unusual items	4.9%	—%	—%		1.7%	—%		4.0%
Interest and financing expenses	-%	-%	—%		—%	—%		2.0%
Income tax expense	—%	-%	—%		-%	—%		3.1%
Non-operating pension and OPEB items	—%	-%	—%		—%	—%		(0.1)%
Adjusted EBITDA Margin	47.2%	30.4%	26.1%		34.7%	8.0%		29.7%
Pro-forma Adjusted EBITDA Margin	47.2%	30.4%	24.8%		34.5%	8.0%		29.4%

See above for adjusted EBITDA margin, a non-GAAP financial measure defined as adjusted EBITDA divided by net sales. See slide 18 for the related reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reporting in accordance with GAAP.

Consolidated Total includes net sales from Corporate (not shown) of \$83 and \$533 in the three months ended June 30, 2018 and 2017, respectively.



Adjusted EBITDA - Continuing Operations (twelve months ended)

	Twelve Months Ended										
(\$ in thousands)		Jun 30, 2017		Sep 30, 2017		Dec 31, 2017		Mar 31, 2018		Jun 30, 2018	
Continuing Operations											
Net income attributable to Albemarle Corporation	\$	884,856	\$	875,306	\$	54,850	\$	135,397	\$	334,525	
Depreciation and amortization		191,853		193,774		196,928		202,188		203,540	
Non-recurring and other unusual items (excluding items associated with interest expense)		88,866		89,214		102,660		101,914		(113,484)	
Interest and financing expenses		117,370		117,216		115,350		60,375		59,093	
Income tax expense		82,223		88,324		431,817		440,207		497,179	
Income from discontinued operations (net of tax)		(583,159)		(559,974)		_		_		_	
Non-operating pension and OPEB items		24,021		23,224		(16,125)		(17,259)		(18,410)	
Adjusted EBITDA	\$	806,030	\$	827,084	\$	885,480	\$	922,822	\$	962,443	
Pro-forma: Net impact of adjusted EBITDA from divested business		(31,186)		(32,798)		(37,123)		(41,287)		(31,521)	
Pro-forma Adjusted EBITDA	\$	774,844	\$	794,286	\$	848,357	\$	881,535	\$	930,922	
Net Sales	\$	2,809,986	\$	2,910,842	\$	3,071,976	\$	3,171,542	\$	3,288,158	
Pro-forma: Net impact of Net Sales from divested business		(94,545)		(97,595)		(99,491)		(106,013)		(80,282)	
Pro-forma Net Sales	\$	2,715,441	\$	2,813,247	\$	2,972,485	\$	3,065,529	\$	3,207,876	
Pro-forma Adjusted EBITDA Margin		29%		28%		29%		29%		29%	

See above for a reconciliation of adjusted EBITDA and pro-forma adjusted EBITDA, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP. EBITDA is defined as Net income attributable to Albemarle Corporation before interest and financing expenses, income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA before discontinued operations and the non-recurring, other unusual and non-operating pension and OPEB items as listed below. Proforma adjusted EBITDA is defined as adjusted EBITDA before the net impact of EBITDA from the divested business.

See above for a reconciliation of pro-forma net sales, the non-GAAP financial measure, to net sales, the most directly comparable financial measure calculated and reported in accordance with GAAP. Proforma net sales is defined as net sales before the net impact of net sales from the divested business.



Adjusted EBITDA - by Segment (twelve months ended)

		Twelve Months Ended													
(\$ in thousands)		Jun 30, 2017		Sep 30, 2017		Dec 31, 2017		Mar 31, 2018		Jun 30, 2018					
Lithium															
Net income attributable to Albemarle Corporation	\$	271,810	\$	314,707	\$	342,992	\$	373,712	\$	409,185					
Depreciation and amortization		85,882		86,409		87,879		92,879		95,744					
Non-recurring and other unusual items		15,094		15,977		15,781		11,223		(698)					
Adjusted EBITDA		372,786		417,093		446,652		477,814		504,231					
Net Sales		834,629		937,461		1,018,885		1,100,688		1,174,430					
Adjusted EBITDA Margin		45%		44%		44%		43%		43%					
Bromine Specialties															
Net income attributable to Albemarle Corporation	\$	189,197	\$	201.336	\$	218,839	\$	219,681	\$	227.615					
Depreciation and amortization	· ·	40.122		40,112	Ť	40.062	Ť	40,701	Ť	40,059					
Adjusted EBITDA		229,319		241,448	_	258,901		260,382		267,674					
Net Sales		812,145		830,572		855,143		861,591		878,160					
Adjusted EBITDA Margin		28%	29%		30%		30%			30%					
Catalysts															
Net income attributable to Albemarle Corporation	\$	243,858	\$	216,405	\$	230,665	\$	229,359	\$	456,252					
Depreciation and amortization		52,105		53,160		54,468		53,855		53,342					
Non-recurring and other unusual items		_		(1,250)		(1,250)		(1,250)		(219,955)					
Adjusted EBITDA		295,963		268,315		283,883		281,964		289,639					
Pro-forma: Net impact of adjusted EBITDA from divested business		(30,425)		(33,323)		(37,123)		(41,287)		(31,521)					
Pro-forma Adjusted EBITDA		265,538		234,992		246,760		240,677		258,118					
Net Sales		1,039,470		1,019,593		1,067,572		1,074,731		1,101,442					
Pro-forma: Net impact of net sales from divested business		(95,015)		(97,595)		(99,491)		(106,013)		(80,282)					
Pro-forma Net Sales	_	944,455		921,998		968,081		968,718		1,021,160					
Pro-forma Adjusted EBITDA Margin		28%		25%		25%		25%		25%					

See above for a reconciliation of adjusted EBITDA and pro-forma adjusted EBITDA on a segment basis, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reporting in accordance with GAAP. EBITDA is defined as earnings before interest and financing expenses, income taxes, and depreciation and amortization. Adjusted EBITDA before the non-recurring, other unusual and non-operating pension and OPEB items as listed above. Pro-forma adjusted EBITDA is defined as adjusted EBITDA before the net impact of EBITDA from the divested business.

See above for a reconciliation of pro-forma net sales on a segment basis, the non-GAAP financial measure, to net sales, the most directly comparable financial measure calculated and reported in accordance with GAAP. Pro-forma net sales is defined as net sales before the net impact of net sales from the divested business.

Adjusted EBITDA supplemental¹

(\$ in thousands)		Twelve Months Ended	Three Months Ended										
	_	Jun 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017			
Adjusted EBITDA	\$	962,443	\$	258,562	\$	248,718	5	245,780	\$	209,383			
Net income attributable to noncontrolling interests		38,208		8,225		7,165		11,295		11,523			
Equity in net income of unconsolidated investments (net of tax)		(87,914)		(18,969)		(20,677)		(29,224)		(19,044)			
Dividends received from unconsolidated investments	_	60,977		4,583		25,462	_	27,486	_	3,446			
Consolidated EBITDA	<u>\$</u>	973,714	\$	252,401	\$	260,668	5	255,337	\$	205,308			
Total Long Term Debt (as reported)	\$	1,615,405											
Off balance sheet obligations and other	_	61,800											
Consolidated Funded Debt	\$	1,677,205											
Less Cash		908,144											
Consolidated Funded Net Debt	\$	769,061	_										
Consolidated Funded Debt to Consolidated EBITDA Ratio		1.7											
Consolidated Funded Net Debt to Consolidated EBITDA Ratio		0.8											

¹This supplemental is for net-debt-to-adjusted EBITDA ratio based on the bank covenant definition.



Diluted EPS

Three Months Ended

		June 30,				
	201	В	2017			
Diluted earnings per share attributable to Albemarle Corporation	\$	2.73	\$	0.92		
Add back:						
Non-operating pension and OPEB items (net of tax)		(0.02)		(0.01)		
Non-recurring and other unusual items (net of tax)						
Utilization of inventory markup		_		0.08		
Restructuring and other		_		0.02		
Acquisition and integration related costs		0.05		0.04		
Albemarle Foundation contribution		0.11		_		
Gain on sale of business		(1.60)		_		
Legal accrual		0.07		_		
Multiemployer plan shortfall contributions		_		0.03		
Other		0.01		0.02		
Discrete tax items		_		0.02		
Total non-recurring and other unusual items		(1.36)		0.21		
djusted diluted earnings per share1	\$	1.36	\$	1.13		

¹Totals may not add due to rounding



Effective Tax Rate

(\$ in thousands)	and equity i	ore income taxes n net income of ted investments	Income tax expense	Effective income tax rate		
Three months ended June 30, 2018:						
As reported	\$	371,819	\$ 80,102	21.5%		
Non-recurring, other unusual and non-operating pension and OPEB items		(187,783)	 (35,292)			
As adjusted	\$	184,036	\$ 44,810	24.4%		
Three months ended June 30, 2017:						
As reported	\$	121,771	\$ 23,130	19.0%		
Non-recurring, other unusual and non-operating pension and OPEB items		28,766	 5,617			
As adjusted	\$	150,537	\$ 28,747	19.1%		

See above for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reporting in accordance with GAAP.



Equity Income and Noncontrolling Interest

		Three Months Ended June 30,								Six Months Ended June 30,									
	_	2	018		2017			_	2		_	2017							
(\$ in thousands)		Equity Income		Noncontrolling Interest	_	Equity Income		Noncontrolling Interest		Equity Income		Noncontrolling Interest	Equity Income		_	Noncontrolling Interest			
Lithium	\$	14,728	\$	_	\$	12,450	\$	_	\$	30,918	\$	_	\$	26,707	\$	_			
Bromine Specialties		_		(8,207)		_		(10,387)		_		(15,356)		_		(21,811)			
Catalysts		4,241		_		2,598		_		8,728		_		9,512		_			
Corporate		_		(18)		_		31		_		(34)		_		11			
Total Company	\$	18,969	\$	(8,225)	\$	15,048	\$	(10,356)	\$	39,646	\$	(15,390)	\$	36,219	\$	(21,800)			





www.albemarle.com